MX2024007035A - Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos. - Google Patents

Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.

Info

Publication number
MX2024007035A
MX2024007035A MX2024007035A MX2024007035A MX2024007035A MX 2024007035 A MX2024007035 A MX 2024007035A MX 2024007035 A MX2024007035 A MX 2024007035A MX 2024007035 A MX2024007035 A MX 2024007035A MX 2024007035 A MX2024007035 A MX 2024007035A
Authority
MX
Mexico
Prior art keywords
cdh6
antibody
immunoconjugate
drug conjugates
binding
Prior art date
Application number
MX2024007035A
Other languages
English (en)
Spanish (es)
Inventor
Shu- Hui LIU
Zhaohui Wang
Jing Shi
Xun Meng
Mingqiao Wang
Rong Pan
Yueyun Jiang
Yiqiang Wang
Original Assignee
Multitude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2021/136994 external-priority patent/WO2023102875A1/en
Application filed by Multitude Therapeutics Inc filed Critical Multitude Therapeutics Inc
Publication of MX2024007035A publication Critical patent/MX2024007035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024007035A 2021-12-10 2022-12-09 Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos. MX2024007035A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111507685 2021-12-10
PCT/CN2021/136994 WO2023102875A1 (en) 2021-12-10 2021-12-10 Anti-cdh6 antibody drug conjugate
PCT/CN2022/137932 WO2023104188A1 (en) 2021-12-10 2022-12-09 Anti-cdh6 antibodies and antibody-drug conjugates thereof

Publications (1)

Publication Number Publication Date
MX2024007035A true MX2024007035A (es) 2024-06-21

Family

ID=86729685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007035A MX2024007035A (es) 2021-12-10 2022-12-09 Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.

Country Status (11)

Country Link
US (1) US20250090677A1 (https=)
EP (1) EP4444360A1 (https=)
JP (1) JP2024545170A (https=)
KR (1) KR20240130160A (https=)
CN (1) CN118302199A (https=)
AU (1) AU2022406708A1 (https=)
CA (1) CA3239715A1 (https=)
IL (1) IL313227A (https=)
MX (1) MX2024007035A (https=)
TW (1) TW202330618A (https=)
WO (1) WO2023104188A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024190815A1 (https=) 2023-03-14 2024-09-19
TW202444427A (zh) 2023-03-31 2024-11-16 日商第一三共股份有限公司 抗CDH6抗體-藥物結合物與HIF-2α抑制劑之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169581A1 (en) * 2015-04-20 2016-10-27 Consejo Superior De Investigaciones Científicas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
WO2018185618A1 (en) * 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TW202532102A (zh) * 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
JP7401456B2 (ja) * 2018-11-14 2023-12-19 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート

Also Published As

Publication number Publication date
CA3239715A1 (en) 2023-06-15
EP4444360A1 (en) 2024-10-16
CN118302199A (zh) 2024-07-05
TW202330618A (zh) 2023-08-01
AU2022406708A1 (en) 2024-06-27
JP2024545170A (ja) 2024-12-05
US20250090677A1 (en) 2025-03-20
KR20240130160A (ko) 2024-08-28
WO2023104188A1 (en) 2023-06-15
IL313227A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
PH12021552831A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2022016180A (es) Conjugados anticuerpo-fármaco que comprenden anticuerpos anti-b7-h3.
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
WO2019215510A8 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
MX2024014288A (es) Agentes de union a nectina-4
WO2019168947A8 (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
MX2022016254A (es) Terapia de combinación de inmunooncología con conjugados de il-2 y anticuerpos anti-egfr.
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
WO2023280092A9 (zh) 抗体药物偶联物及其应用
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
MX2025006057A (es) Conjugados anticuerpo-farmaco anti-cea y metodos de uso
MX2025007664A (es) Conjugados de anticuerpos farmacos b7h3
MX2025005811A (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
MX2023007178A (es) Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
MX2024009292A (es) Anticuerpos anti-her2/trop2 y usos de los mismos.
MX2024004222A (es) Conjugados anticuerpo-farmaco y metodos para fabricar los mismos.
Kellner et al. Human kappa light chain targeted Pseudomonas exotoxin A—identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development
WO2023225336A8 (en) Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
MX2025015337A (es) Anticuerpos de nectina-4 y conjugados anticuerpo-farmaco
TW202617781A (zh) Ｎｅｃｔｉｎ－４抗體及抗體藥物結合物